NAS150

Double Enzyme Mimetic

NAS150 has demonstrated efficacy in multiple models of pulmonary fibrosis (radiation and chemicals – chemotherapeutics, toxic industrial chemicals and chemical warfare agents) supporting expectations of success in mitigating fibrosis related “Long Haul” syndrome  aka SARS-CoV-2 Pulmonary Fibrosis

NAS

Currently Privately Held

New Amsterdam Sciences has worked hard for many years and with many experts on board to bring our powerful  dual antioxidant, ROS balancing, anti-inflammatory  Platform technology candidates to a place where patients will benefit. We expect that NAS150 can effectively treat the underlying cause of acute COVID-19 as well as other inflammatory conditions driven by imbalances in ROS

 

Covid Hot Spots